AKT1 and melanoma: It has been shown that in resistant cells, melanoma progresses through downstream signaling of the RAF and PI3K/Akt proteins (Dhomen and Marais, 2009), thus, we performed a high-throughput screening to identify a dual inhibitor against the V600E mutated B-RAF and Akt targets.